Who are SPD503-AM's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azilect, Auromid, Selegiline Hydrochloride, Humoryl, Parnate, Nardil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spd503-am.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SPD503-AM — Competitive Intelligence Brief

SPD503-AM (SPD503-AM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine oxidase inhibitor. Area: Psychiatry/Neurology.

phase 3 Monoamine oxidase inhibitor Monoamine oxidase (MAO) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

SPD503-AM (SPD503-AM) — Shire. SPD503-AM is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SPD503-AM TARGET	SPD503-AM	Shire	phase 3	Monoamine oxidase inhibitor	Monoamine oxidase (MAO)
Azilect	RASAGILINE	Teva	marketed	Monoamine Oxidase Inhibitor	5-hydroxytryptamine receptor 6	2006-01-01
Auromid	MOCLOBEMIDE		marketed	Monoamine Oxidase Inhibitors	Amine oxidase [flavin-containing] A	1990-01-01
Selegiline Hydrochloride	SELEGILINE	Somerset	marketed	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1989-01-01
Humoryl	TOLOXATONE		marketed	Monoamine Oxidase Inhibitors	Amine oxidase [flavin-containing] A	1984-01-01
Parnate	TRANYLCYPROMINE	Advanz	marketed	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1961-01-01
Nardil	Phenelzine Sulfate	Pfizer	marketed	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1961-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine oxidase inhibitor class)

Shire · 2 drugs in this class
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPD503-AM — Competitive Intelligence Brief. https://druglandscape.com/ci/spd503-am. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab